Overall, in these 3 studies of combinatory strategy, the objective response rate remained very low: 8 PR were observed in 59 patients included.82–84 Moreover, in association with IL-2 and alpha-interferon (α-IFN), R24 showed no objective response in a phase Ib trial including 21 metastatic melanomas. This evidence concerns the gene IL2 and metastatic melanoma.